Inclusion Criteria:

          -  Histologic confirmation of ovarian, primary peritoneal or fallopian tube cancer of any
             subtype

          -  Prior consent to have tumors used for unspecified future research

          -  Ability to provide written informed consent

          -  Willing to agree to periodic contact with a member of the study team during the period
             that the cancer has not recurred and/or has not become platinum resistant

          -  Willing to agree that the local medical oncologist may be informed that patient has
             agreed to participate in the study

          -  Platinum resistant or refractory ovarian, primary peritoneal or fallopian tube cancer
             of any subtype; Note: platinum-sensitive disease is allowed in cases where there is a
             contraindication to platinum-based therapy (i.e., allergy to platinum); this must be
             reviewed and approved by the Principal Investigator

          -  Successful Avatar engraftment with successful expansion and treatment outcome of
             Avatar therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status (ECOG performance status
             [PS]) of 0, 1 or 2

          -  Measurable disease or non-measurable disease; for patients with non-measureable
             disease, they must also have a cancer antigen (CA)-125 measurement of > 35 U/mL or 2 X
             their documented nadir on 2 separate measurements 1 week apart

          -  The following laboratory values obtained =< 21 days prior to registration; complete
             blood count (CBC), sodium, potassium, aspartate aminotransferase (AST), bilirubin and
             creatinine are to be obtained pre-study; Note: treatment initiation and dosing
             modification should be performed at the individual investigators discretion and be
             consistent with the product label and their medical practice

          -  Negative urine or serum pregnancy test performed =< 7 days prior to registration, for
             women of child bearing potential only

          -  Willing to return to enrolling institution for follow-up or have a local physician
             willing to submit response and outcome data; Note: any and all therapy, potentially in
             its entirety, may be conducted outside of the Mayo Clinic

        Exclusion Criteria:

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

          -  Prior treatment with Doxil, topotecan, Gemzar or Taxol chemotherapy for
             platinum-resistant cancer; Note: Allowed prior therapy with Doxil or Gemzar if given
             for platinum sensitive disease in combination with a platinum drug AND the Avatar data
             indicates a drug other than Doxil or Gemzar would be effective; Note: Allowed prior
             therapies for patients following confirmation of platinum-resistant cancer include:

               -  Therapeutic antibodies, such as bevacizumab

               -  Small molecule kinase inhibitors, such as pazopanib

               -  Vaccines and immunotherapy All of these exceptions should be confirmed with the
                  Principal Investigator (PI) prior to registration

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)
             positive and currently receiving antiretroviral therapy; Note: patients known to be
             HIV positive, but without clinical evidence of an immunocompromised state, are
             eligible for this trial

          -  Uncontrolled intercurrent illness judged by the treating investigator to preclude
             treatment with chemotherapy

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm

          -  Other active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanotic
             skin cancer or carcinoma-in-situ of the cervix; Note: if there is a history of prior
             malignancy, they must not be receiving treatment for their cancer